Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model.

Conclusions: The supplementation of rhTPO and IL-2 to a GC regime effectively reduced tumor sizes and restored the platelet count in a human lung cancer mouse model. PMID: 31903256 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/31903256?dopt=Abstract

Source: Journal of Thoracic Disease - January 8, 2020 Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research

More News: Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer | Respiratory Medicine | Thrombocytopenia